We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+25.2%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$697M
AUM Growth
-$38.9M
Cap. Flow
-$135M
Cap. Flow %
-19.43%
Top 10 Hldgs %
45.64%
Holding
96
New
21
Increased
21
Reduced
26
Closed
24

Top Buys

Rank Stock Value
1
VCEL icon
Vericel Corp
VCEL
+$12.7M
2
NARI
Inari Medical, Inc. Common Stock
NARI
+$8.91M
3
CCCC icon
C4 Therapeutics
CCCC
+$8.29M
4
CELC icon
Celcuity
CELC
+$7.84M
5
HCA icon
HCA Healthcare
HCA
+$7.74M

Top Sells

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$27.1M
2
UTHR icon
United Therapeutics
UTHR
+$26.9M
3
CVS icon
CVS Health
CVS
+$18.4M
4
NVST icon
Envista
NVST
+$15.7M
5
LLY icon
Eli Lilly
LLY
+$14.8M

Sector Composition

Rank Sector Weight
1 Healthcare 97.09%
2 Consumer Staples 1.8%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ESTA icon
51
Establishment Labs
ESTA
$2.33B
$2.62M 0.38%
39,920
-22,700
-36% -$1.37M
PTGX icon
52
Protagonist Therapeutics
PTGX
$9.4B
$2.57M 0.37%
+236,000
New +$1.99M
TXG icon
53
10x Genomics
TXG
$5.79B
$2.55M 0.37%
+70,000
New +$2.29M
ISRG icon
54
Intuitive Surgical
ISRG
$132B
$2.55M 0.37%
9,600
-25,200
-72% -$6.14M
VTYX
55
DELISTED
Ventyx Biosciences
VTYX
$2.26M 0.32%
+69,000
New +$2.04M
NEOG icon
56
Neogen
NEOG
$2.46B
$2.19M 0.31%
+143,500
New +$2.04M
PRDS
57
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$2.11M 0.3%
+1,250,000
New +$1.58M
PEN icon
58
Penumbra
PEN
$12.8B
$2.07M 0.3%
+9,300
New +$1.82M
KDNY
59
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$2.04M 0.29%
78,000
– –
AMLX icon
60
Amylyx Pharmaceuticals
AMLX
$2.69B
$1.87M 0.27%
50,636
-378,700
-88% -$13.4M
LYRA
61
DELISTED
LYRA THERAPEUTICS INC
LYRA
$1.86M 0.27%
11,848
– –
KYNB
62
Kyntra Bio
KYNB
$28.3M
$1.82M 0.26%
4,539
-4,822
-52% -$1.85M
XENE icon
63
Xenon Pharmaceuticals
XENE
$6.24B
$1.5M 0.22%
38,000
-58,800
-61% -$2.14M
PVLA
64
Palvella Therapeutics
PVLA
$2.23B
$1.04M 0.15%
12,500
-39,186
-76% -$3.15M
CRSP icon
65
CRISPR Therapeutics
CRSP
$4.99B
$894K 0.13%
22,000
– –
CUTR
66
DELISTED
Cutera, Inc.
CUTR
$884K 0.13%
20,000
-235,792
-92% -$10.8M
XLO icon
67
Xilio Therapeutics
XLO
$61M
$610K 0.09%
16,210
-16,194
-50% -$546K
LUNG icon
68
Pulmonx
LUNG
$88M
$599K 0.09%
+71,000
New +$675K
ANAB icon
69
AnaptysBio
ANAB
$1.62B
$456K 0.07%
14,727
-49,300
-77% -$1.39M
YMAB
70
DELISTED
Y-mAbs Therapeutics
YMAB
$425K 0.06%
87,182
– –
KIDS icon
71
OrthoPediatrics
KIDS
$586M
$297K 0.04%
+7,471
New +$311K
PEPG icon
72
PepGen
PEPG
$167M
$134K 0.02%
10,000
-120,000
-92% -$1.55M
ADVM
73
DELISTED
Adverum Biotechnologies
ADVM
– –
-558,779
Closed -$5.31M
ALNY icon
74
Alnylam Pharmaceuticals
ALNY
$28.9B
– –
-27,000
Closed -$5.4M
APLS
75
DELISTED
Apellis Pharmaceuticals
APLS
– –
-13,400
Closed -$915K
1 2
3
4

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return
QT
Quantbot Technologies New York $2.44B AUM 17.13% 1-Year Est. Return

Soleus Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, Soleus Capital Management held 96 positions worth $697M, down 5.3% from $736M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Soleus Capital Management withdrew a net $135M in Q4 2022, closing 24 positions and reducing 26 holdings. Its most notable exit was Envista, an estimated $15.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 93% a quarter earlier, followed by Consumer Staples and Financials.

Against the trend, Soleus Capital Management opened a new position in HCA Healthcare worth $8.29M.

  • Soleus Capital Management's largest Q4 2022 buy was HCA Healthcare: 34,550 shares worth $8.29M.
  • Soleus Capital Management added most to Vericel Corp in Q4 2022, an estimated $12.7M increase.
  • Soleus Capital Management's biggest Q4 2022 reduction was Illumina, cutting an estimated $27.1M.
  • Soleus Capital Management fully exited Envista in Q4 2022, selling an estimated $15.7M.
  • Soleus Capital Management's ten largest holdings make up 46% of its $697M portfolio in Q4 2022.
  • Soleus Capital Management opened 21 new positions and closed 24 in Q4 2022.
  • Soleus Capital Management's portfolio value fell 5.3% quarter-over-quarter to $697M.

Based on Soleus Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.